Multinational cost‐effectiveness analysis of empagliflozin for heart failure patients with ejection...
Multinational cost‐effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40
About this item
Full title
Author / Creator
Publisher
Oxford: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Oxford: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Aims
Heart failure is a chronic progressive condition, with considerable burden on patients' quality of life and economic burden for the healthcare systems. Before the approval of empagliflozin, there were no proven effective treatments for patients with heart failure with left ventricular ejection fraction (HF LVEF) > 40%. The aim of this study...
Alternative Titles
Full title
Multinational cost‐effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_47d66ea7e2344e5e96c1b2e9db40f2eb
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_47d66ea7e2344e5e96c1b2e9db40f2eb
Other Identifiers
ISSN
2055-5822
E-ISSN
2055-5822
DOI
10.1002/ehf2.14470
